Sp1084

HOW DOES GUT MICROBIOTA DRIVE METABOLIC SYNDROME?

Date
May 9, 2023
Explore related products in the following collection:

Society: AGA

In this session we will learn about the exciting advances in mechanisms by which microbial metabolites as well can drive metabolic disorders and the pipeline of potential microbial therapeutics to treat metabolic disorders.

Presenter

Speaker Image for Mariana Byndloss
Vanderbilt University Medical Center

Tracks

Related Products

Thumbnail for ENCAPSULATED MICROBIOTA TRANSPLANT THERAPY IMPROVES PARTIAL MAYO SCORES IN ULCERATIVE COLITIS AND INDUCES RAPID ENGRAFTMENT COMPARED TO PLACEBO CONTROL
ENCAPSULATED MICROBIOTA TRANSPLANT THERAPY IMPROVES PARTIAL MAYO SCORES IN ULCERATIVE COLITIS AND INDUCES RAPID ENGRAFTMENT COMPARED TO PLACEBO CONTROL
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
Thumbnail for AUPHOS, A NOVEL DRUG THAT RESTORES INTESTINAL HOMEOSTATIS BY CORRECTING DYSBIOSIS IN INFLAMMATORY BOWEL DISEASES
AUPHOS, A NOVEL DRUG THAT RESTORES INTESTINAL HOMEOSTATIS BY CORRECTING DYSBIOSIS IN INFLAMMATORY BOWEL DISEASES
BACKGROUND: Enterochromaffin cells (ECs) are specialized gastrointestinal (GI) epithelial cells that transduce luminal forces and chemicals into release of signal molecules including serotonin (5-HT) to alter GI function including mucosal ion transport…
Thumbnail for AGA Gut Microbial Metabolites as Central Regulators in Metabolic Disorders
AGA Gut Microbial Metabolites as Central Regulators in Metabolic Disorders
In this session we will learn about the exciting advances in mechanisms by which microbial metabolites as well can drive metabolic disorders and the pipeline of potential microbial therapeutics to treat metabolic disorders…
Thumbnail for MONITORING OF CALPROTECTIN IN INFLAMMATORY BOWEL DISEASE USING A SWEAT BASED WEARABLE DEVICE
MONITORING OF CALPROTECTIN IN INFLAMMATORY BOWEL DISEASE USING A SWEAT BASED WEARABLE DEVICE
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…